| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | IMFINZI (Durvalumab) +/- tremelimumab - (NEPTUNE) | Lung cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | IMFINZI (Durvalumab) +/- tremelimumab - (EAGLE) | Head & neck cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | IMFINZI (Durvalumab) +/- tremelimumab - (MYSTIC) | Lung cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | FASENRA (benralizumab) - GALATHEA | Chronic obstructive pulmonary disease (COPD) | Phase 3 | Trial Discontinued | Subcutaneous | Respiratory |
| AstraZeneca PLC | LYNPARZA (olaparib) - SOLO 3 | Third-line ovarian cancer | Phase 3 | Trial Completed | Oral | Oncology |
| AstraZeneca PLC | Lanabecestat (AZD3293) - AMARANTH | Early Alzheimer's disease | Phase 3 | Trial Discontinued | Oral | Neurology |
| AstraZeneca PLC | AZD1222 (D8110C00001) | COVID-19 vaccine | Phase 3 | Trial Discontinued | Intramuscular | COVID-19 |
| AstraZeneca PLC | IMFINZI (Durvalumab) +/- tremelimumab - (MYSTIC) | Lung cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |